MINI FUTURE LONG - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 13:18:35 2024-07-16 EDT | ||
| 14.04 EUR / 14.3 EUR | +0.43% |
|
| Current month | -3.75% | ||
| 1 month | -1.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 14.19 | +0.57% |
| 24-07-15 | 14.11 | -3.69% |
| 24-07-12 | 14.65 | -3.93% |
| 24-07-11 | 15.25 | +3.46% |
| 24-07-10 | 14.74 | -4.35% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 08:53 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG3BC7 |
| ISIN | DE000MG3BC74 |
| Date issued | 2024-04-30 |
| Strike | 125.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.42 € |
|---|---|
| Lowest since issue | 7.18 € |
| Spread | 0.26 € |
| Spread % | 1.81% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
